The role of PET in dementia diagnosis and treatment

Mehta, Lina; Thomas, Smitha

doi:10.37549/ar1901

Cited by 9 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AD = Alzheimer's disease; CT = computed tomography; MRI = magnetic resonance imaging; FDG-PET = [ 18 F]fluorodeoxyglucosepositron emission tomography; rCBF-SPECT = regional cerebral blood flow-single photon emission computed tomography. a and specificity of 86% of FDG-PET for the diagnosis of AD has been reported in previous studies(Mehta and Thomas 2012) Recently, it has been concluded that FDG PET is independent from "N" biomarker proposed in AT(N) framework for AD diagnosis as consumption of glucose driven by astrocytes, rather than neurons(Ou and others 2019).Figures2 to 4are examples of FDG-PET imaging corresponding to the Mini-…”

mentioning

confidence: 65%

“…It is established that hippocampal hypo-metabolism occurs in the early stages of AD and that neocortical involvement occurs in later stages of the illness ( Ishii and others 1998 ), with progression occurring in a stereotypical pattern via brain networks ( Brown and others 2019 ). A sensitivity of 93% to 97% and specificity of 86% of FDG-PET for the diagnosis of AD has been reported in previous studies ( Mehta and Thomas 2012 ) Recently, it has been concluded that FDG PET is independent from “N” biomarker proposed in AT(N) framework for AD diagnosis as consumption of glucose driven by astrocytes, rather than neurons ( Ou and others 2019 ).…”

Section: Fdg-pet Imaging In Admentioning

confidence: 75%

“…Thus, it can be used to measure neuronal dysfunction, which is inversely proportional to the glucose uptake ( Hoffman and others 2000 ; Nasrallah and Dubroff 2013 ). A distinct pattern of hypo-metabolism ( Figure 1 ) on FDG-PET can distinguish AD from other causes of dementia and it can distinguish people with AD from healthy controls with sensitivity and specificity of 93% to 97% and 86% ( Mehta and Thomas 2012 ). However, to differentiate people with AD from people with dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD) the sensitivity remains at 99% but specificity drops to 71% and 65%, respectively ( Daniela and others 2014 ; Mosconi and others 2008 ).…”

Section: Fdg-pet Imaging In Admentioning

confidence: 99%

See 2 more Smart Citations

Alzheimer’s Dementia: The Emerging Role of Positron Emission Tomography

Tripathi

Murray

2021

Neuroscientist

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is the most common cause of dementia and accounts for approximately 50% to 80% of all cases of dementia. The diagnosis of probable AD is based on clinical criteria and overlapping clinical features pose a challenge to accurate diagnosis. However, neuroimaging has been included as a biomarker in various published criteria for the diagnosis of probable AD, in the absence of a confirmatory diagnostic test during life. Advances in neuroimaging techniques and their inclusion in diagnostic and research criteria for the diagnosis of AD includes the use of positron emission tomography (PET) imaging as a biomarker in various therapeutic and prognostic studies in AD. The development and application of a range of PET tracers will allow more detailed assessment of people with AD and will improve diagnostic specificity and targeted therapy of AD. The aim of this review is to summarize current evidence on PET imaging using the non-specific tracer [18F]fluorodeoxyglucose and specific tracers that target amyloid and tau pathology in people with AD.

show abstract

mentioning

confidence: 65%

Section: Fdg-pet Imaging In Admentioning

confidence: 75%

Section: Fdg-pet Imaging In Admentioning

confidence: 99%

See 1 more Smart Citation

Alzheimer’s Dementia: The Emerging Role of Positron Emission Tomography

Tripathi

Murray

2021

Neuroscientist

View full text Add to dashboard Cite

show abstract

“…Positron Emission Tomography (PET) is a powerful tool in early detection and treatment of dementia. 1 In addition to imaging metabolism in Alzheimer's disease (AD) using 18 F-FDG, 2 amyloid and tau radioligands have great potential in imaging AD as they bind with high affinity and specificity to the amyloid and tau structures which are the pathological hallmarks of the disease. PET scans can also be used to diagnose brain tumors and moni-tor recurrence after treatment.…”

Section: Introductionmentioning

confidence: 99%

MR‐based motion correction for PET imaging using wired active MR microcoils in simultaneous PET‐MR: Phantom study

et al. 2014

View full text Add to dashboard Cite

Purpose: Artifacts caused by head motion present a major challenge in brain positron emission tomography (PET) imaging. The authors investigated the feasibility of using wired active MR microcoils to track head motion and incorporate the measured rigid motion fields into iterative PET reconstruction. Methods: Several wired active MR microcoils and a dedicated MR coil-tracking sequence were developed. The microcoils were attached to the outer surface of an anthropomorphic 18 F-filled Hoffman phantom to mimic a brain PET scan. Complex rotation/translation motion of the phantom was induced by a balloon, which was connected to a ventilator. PET list-mode and MR tracking data were acquired simultaneously on a PET-MR scanner. The acquired dynamic PET data were reconstructed iteratively with and without motion correction. Additionally, static phantom data were acquired and used as the gold standard. Results: Motion artifacts in PET images were effectively removed by wired active MR microcoil based motion correction. Motion correction yielded an activity concentration bias ranging from −0.6% to 3.4% as compared to a bias ranging from −25.0% to 16.6% if no motion correction was applied. The contrast recovery values were improved by 37%-156% with motion correction as compared to no motion correction. The image correlation (mean ± standard deviation) between the motion corrected (uncorrected) images of 20 independent noise realizations and static reference was R 2 = 0.978 ± 0.007 (0.588 ± 0.010, respectively). Conclusions: Wired active MR microcoil based motion correction significantly improves brain PET quantitative accuracy and image contrast.

show abstract